Advanced Search

Project: Screening for HIV Infection in Asymptomatic, Nonpregnant Adolescents and Adults [Entered Retrospectively]

Public Report Complete



Project Summary

Title and Description


Key Questions


Associated Extraction Forms

Title Created by Key Questions Addressed Form Notes
Key Questions 1-5 Sara Grusing 1, 2, 3, 4, 5


Associated Studies (each link opens a new tab)

Title Author Year
Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older. Lodi S., Costagliola D., Sabin C., Del Amo J., Logan R., Abgrall S., Reiss P., van Sighem A., Jose S., Blanco JR., Hernando V., Bucher HC., Kovari H., Segura F., Ambrosioni J., Gogos CA., Pantazis N., Dabis F., Vandenhende MA., Meyer L., Seng R., Gill MJ., Krentz H., Phillips AN., Porter K., Grinsztejn B., Pacheco AG., Muga R., Tate J., Justice A., Hernán MA. 2017
Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μL: secondary outcome results from a randomised controlled trial. O'Connor J., Vjecha MJ., Phillips AN., Angus B., Cooper D., Grinsztejn B., Lopardo G., Das S., Wood R., Wilkin A., Klinker H., Kantipong P., Klingman KL., Jilich D., Herieka E., Denning E., Abubakar I., Gordin F., Lundgren JD. 2017
Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. Lodi S., Phillips A., Logan R., Olson A., Costagliola D., Abgrall S., van Sighem A., Reiss P., Miró JM., Ferrer E., Justice A., Gandhi N., Bucher HC., Furrer H., Moreno S., Monge S., Touloumi G., Pantazis N., Sterne J., Young JG., Meyer L., Seng R., Dabis F., Vandehende MA., Pérez-Hoyos S., Jarrín I., Jose S., Sabin C., Hernán MA. 2015
Age at Entry Into Care, Timing of Antiretroviral Therapy Initiation, and 10-Year Mortality Among HIV-Seropositive Adults in the United States. Edwards JK., Cole SR., Westreich D., Mugavero MJ., Eron JJ., Moore RD., Mathews WC., Hunt P., Williams C. 2015
Initiation of antiretroviral therapy at high CD4+ cell counts is associated with positive treatment outcomes. Lima VD., Reuter A., Harrigan PR., Lourenço L., Chau W., Hull M., Mackenzie L., Guillemi S., Hogg RS., Barrios R., Montaner JS. 2015
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. Danel C., Moh R., Gabillard D., Badje A., Le Carrou J., Ouassa T., Ouattara E., Anzian A., Ntakpé JB., Minga A., Kouame GM., Bouhoussou F., Emieme A., Kouamé A., Inwoley A., Toni TD., Ahiboh H., Kabran M., Rabe C., Sidibé B., Nzunetu G., Konan R., Gnokoro J., Gouesse P., Messou E., Dohoun L., Kamagate S., Yao A., Amon S., Kouame AB., Koua A., Kouamé E., Ndri Y., Ba-Gomis O., Daligou M., Ackoundzé S., Hawerlander D., Ani A., Dembélé F., Koné F., Guéhi C., Kanga C., Koule S., Séri J., Oyebi M., Mbakop N., Makaila O., Babatunde C., Babatounde N., Bleoué G., Tchoutedjem M., Kouadio AC., Sena G., Yededji SY., Assi R., Bakayoko A., Mahassadi A., Attia A., Oussou A., Mobio M., Bamba D., Koman M., Horo A., Deschamps N., Chenal H., Sassan-Morokro M., Konate S., Aka K., Aoussi E., Journot V., Nchot C., Karcher S., Chaix ML., Rouzioux C., Sow PS., Perronne C., Girard PM., Menan H., Bissagnene E., Kadio A., Ettiegne-Traore V., Moh-Semdé C., Kouame A., Massumbuko JM., Chêne G., Dosso M., Domoua SK., N'Dri-Yoman T., Salamon R., Eholié SP., Anglaret X. 2015
Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Grinsztejn B., Hosseinipour MC., Ribaudo HJ., Swindells S., Eron J., Chen YQ., Wang L., Ou SS., Anderson M., McCauley M., Gamble T., Kumarasamy N., Hakim JG., Kumwenda J., Pilotto JH., Godbole SV., Chariyalertsak S., de Melo MG., Mayer KH., Eshleman SH., Piwowar-Manning E., Makhema J., Mills LA., Panchia R., Sanne I., Gallant J., Hoffman I., Taha TE., Nielsen-Saines K., Celentano D., Essex M., Havlir D., Cohen MS. 2014
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. Lundgren JD., Babiker AG., Gordin F., Emery S., Grund B., Sharma S., Avihingsanon A., Cooper DA., Fätkenheuer G., Llibre JM., Molina JM., Munderi P., Schechter M., Wood R., Klingman KL., Collins S., Lane HC., Phillips AN., Neaton JD. 2015
Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: the D: A: D study. Bruyand M., Ryom L., Shepherd L., Fatkenheuer G., Grulich A., Reiss P., de Wit S., D Arminio Monforte A., Furrer H., Pradier C., Lundgren J., Sabin C. 2015
Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. Mocroft A., Lundgren JD., Ross M., Fux CA., Reiss P., Moranne O., Morlat P., Monforte Ad., Kirk O., Ryom L. 2016
Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease events. Monforte Ad., Reiss P., Ryom L., El-Sadr W., Dabis F., De Wit S., Worm SW., Law MG., Weber R., Kirk O., Pradier C., Phillips AN., Lundgren JD., Sabin CA. 2013
Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons. Ryom L., Lundgren JD., De Wit S., Kovari H., Reiss P., Law M., El-Sadr W., Monforte AD., Mocroft A., Smith C., Fontas E., Dabis F., Phillips A., Sabin C. 2016
Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration. Sabin CA., Reiss P., Ryom L., Phillips AN., Weber R., Law M., Fontas E., Mocroft A., de Wit S., Smith C., Dabis F., d'Arminio Monforte A., El-Sadr W., Lundgren JD. 2016
No Evidence of an Association Between Efavirenz Exposure and Suicidality Among HIV Patients Initiating Antiretroviral Therapy in a Retrospective Cohort Study of Real World Data. Nkhoma ET., Coumbis J., Farr AM., Johnston SS., Chu BC., Rosenblatt LC., Seekins D., Villasis-Keever A. 2016
Lack of association between use of efavirenz and death from suicide: evidence from the D:A:D study. Smith C., Ryom L., Monforte Ad., Reiss P., Mocroft A., El-Sadr W., Weber R., Law M., Sabin C., Lundgren J. 2014
No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. Ding X., Andraca-Carrera E., Cooper C., Miele P., Kornegay C., Soukup M., Marcus KA. 2012
Comparative Safety and Neuropsychiatric Adverse Events Associated With Efavirenz Use in First-Line Antiretroviral Therapy: A Systematic Review and Meta-Analysis of Randomized Trials. Ford N., Shubber Z., Pozniak A., Vitoria M., Doherty M., Kirby C., Calmy A. 2015
Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs study. Kovari H., Sabin CA., Ledergerber B., Ryom L., Worm SW., Smith C., Phillips A., Reiss P., Fontas E., Petoumenos K., De Wit S., Morlat P., Lundgren JD., Weber R. 2013
Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. Ryom L., Mocroft A., Kirk O., Worm SW., Kamara DA., Reiss P., Ross M., Fux CA., Morlat P., Moranne O., Smith C., Lundgren JD. 2013
Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy. Kowalska JD., Reekie J., Mocroft A., Reiss P., Ledergerber B., Gatell J., d'Arminio Monforte A., Phillips A., Lundgren JD., Kirk O. 2012
Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. Rockstroh JK., DeJesus E., Lennox JL., Yazdanpanah Y., Saag MS., Wan H., Rodgers AJ., Walker ML., Miller M., DiNubile MJ., Nguyen BY., Teppler H., Leavitt R., Sklar P. 2013
Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results. Arribas JR., Thompson M., Sax PE., Haas B., McDonald C., Wohl DA., DeJesus E., Clarke AE., Guo S., Wang H., Callebaut C., Plummer A., Cheng A., Das M., McCallister S. 2017
Association of tenofovir exposure with kidney disease risk in HIV infection. Scherzer R., Estrella M., Li Y., Choi AI., Deeks SG., Grunfeld C., Shlipak MG. 2012
Association between tenofovir exposure and reduced kidney function in a cohort of HIV-positive patients: results from 10 years of follow-up. Laprise C., Baril JG., Dufresne S., Trottier H. 2013
Antiretrovirals, Fractures, and Osteonecrosis in a Large International HIV Cohort. Borges ÁH., Hoy J., Florence E., Sedlacek D., Stellbrink HJ., Uzdaviniene V., Tomazic J., Gargalianos-Kakolyris P., Schmid P., Orkin C., Pedersen C., Leen C., Pradier C., Mulcahy F., Ridolfo AL., Staub T., Maltez F., Weber R., Flamholc L., Kyselyova G., Lundgren JD., Mocroft A. 2017
Risk of cardiovascular events associated with current exposure to HIV antiretroviral therapies in a US veteran population. Desai M., Joyce V., Bendavid E., Olshen RA., Hlatky M., Chow A., Holodniy M., Barnett P., Owens DK. 2015
Real-World Assessment of Renal and Bone Safety among Patients with HIV Infection Exposed to Tenofovir Disoproxil Fumarate-Containing Single-Tablet Regimens. Nkhoma ET., Rosenblatt L., Myers J., Villasis-Keever A., Coumbis J. 2016
Antiretroviral Therapy for the Prevention of HIV-1 Transmission. Cohen MS., Chen YQ., McCauley M., Gamble T., Hosseinipour MC., Kumarasamy N., Hakim JG., Kumwenda J., Grinsztejn B., Pilotto JH., Godbole SV., Chariyalertsak S., Santos BR., Mayer KH., Hoffman IF., Eshleman SH., Piwowar-Manning E., Cottle L., Zhang XC., Makhema J., Mills LA., Panchia R., Faesen S., Eron J., Gallant J., Havlir D., Swindells S., Elharrar V., Burns D., Taha TE., Nielsen-Saines K., Celentano DD., Essex M., Hudelson SE., Redd AD., Fleming TR. 2016
Depression and Suicidal Ideation Among HIV-Infected Adults Receiving Efavirenz Versus Nevirapine in Uganda: A Prospective Cohort Study. Chang JL., Tsai AC., Musinguzi N., Haberer JE., Boum Y., Muzoora C., Bwana M., Martin JN., Hunt PW., Bangsberg DR., Siedner MJ. 2018




Creative Commons LicenseThis graphic notice indicates that you are leaving this Federal Government Web site and entering a non-Federal Web site. Creative Commons  
The data contained in this project are distributed under the terms of the Creative Commons Attribution-NonCommerical license, which permits the use, dissemination, and reproduction in any medium, provided the original work is properly cited, and that the use is non-commercial and otherwise in compliance with the license. See: https://creativecommons.org/licenses/by-nc/3.0/